Burcon prices prospectus offering


    VANCOUVER, June 10 /CNW/ - Burcon NutraScience Corporation (TSXV -BU)
("Burcon" or the "Corporation") is pleased to announce that, further to its
press release dated May 28, 2009, it has entered into an agency agreement (the
"Agency Agreement") with a syndicate of agents led by Paradigm Capital Inc.
and including BMO Capital Markets and Haywood Securities Inc. (collectively
the "Agents"). Under the terms of the Agency Agreement, the Agents will offer
(the "Offering"), on a best efforts basis, up to 2,609,000 common shares at a
price of $5.75 per common share (the "Issue Price") for gross proceeds of
    Burcon has also granted the Agents an over-allotment option, exercisable
in whole or in part for a period of 30 days following the closing of the
Offering, to arrange for the sale of up to an additional 391,350 common shares
at the Issue Price for additional gross proceeds of approximately $2,250,000.
    The Corporation anticipates filing a final short form prospectus on June
10, 2009 with the securities regulatory authorities in the Provinces of
British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick and
Nova Scotia in connection with the Offering. The Offering is expected to close
on or about June 18, 2009.
    On June 1, 2009 the Toronto Stock Exchange (the "TSX") conditionally
approved the Corporation's application for listing its common shares. Listing
of the common shares will be subject to fulfilling all of the requirements of
the TSX by August 28, 2009, including raising gross proceeds of $10 million
from the Offering. It is the Corporation's intention to satisfy the listing
requirements and list the common shares of the Corporation, as well as the
Shares sold pursuant to the Offering, on the TSX. Subject to the foregoing,
the Corporation anticipates that the Common Shares of the Corporation will be
listed and posted for trading on the TSX under the same symbol "BU" on the
closing date.
    Closing is subject to certain conditions, including, but not limited to,
the receipt of all necessary approvals including the approval of the
applicable securities regulatory authorities and the TSX Venture Exchange and
the TSX.
    The net proceeds of the Offering shall be used for continued research and
development of the soy protein isolate extraction and purification technology
(CLARISOY(TM)), further refining of the canola protein isolate extraction and
purification technology (Puratein(R) and Supertein(TM)), filing new patent
applications and expanding the Corporation's intellectual property portfolio,
and for general working capital purposes, all as more particularly set out in
the final prospectus.

    This press release is not an offer to sell or the solicitation of an
offer to buy the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to qualification or registration
under the securities laws of such jurisdiction. The securities being offered
have not been, nor will they be, registered under the United States Securities
Act of 1933, as amended, and such securities may not be offered or sold within
the United States or to, or for the account or benefit of, U.S. persons absent
registration or an applicable exemption from U.S. registration requirements.

    "Johann F. Tergesen"
    Johann F. Tergesen
    President and Chief Operating Officer

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.

    This press release contains forward-looking statements that involve risks
and uncertainties. These forward-looking statements relate to, among other
things, the Corporation's proposed offering and use of proceeds, the proposed
listing of the Corporation's common shares on the TSX, plans and timing for
the introduction or enhancement of our products, statements about future
market conditions, supply and demand conditions, and other expectations,
intentions and plans contained in this press release that are not historical
fact. Our expectations regarding the prospect for future success depend upon
our ability to develop and sell products, which we do not produce today and
cannot be sold without further research and development. When used in this
press release, the words "goal", "intend", "believes", "potential",
"expected", "anticipates", "will be", "TSX listing" and "completion of the
offering" and similar expressions, generally identify forward-looking
statements. These statements reflect our current expectations. They are
subject to a number of risks and uncertainties. In light of the many risks and
uncertainties surrounding the development of a source of protein from canola
meal, you should understand that we cannot assure you that the forward looking
statements contained in this press release will be realized.

For further information:

For further information: Jade Cheng, Chief Financial Officer, Burcon
NutraScience Corporation, (604) 733-0896, (888) 408-7960, toll-free
jcheng@burcon.ca, www.burcon.ca; AXINO AG: Wolfgang Seybold, Investor
Relations Europe, AXINO AG, Königstrasse 26, 70173 Stuttgart, Germany, Tel.
+49-711-25 35 92-30, Fax +49-711-25 35 92-33, seybold@axino.de,

Organization Profile

Burcon NutraScience Corporation

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890